Paper9448657
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Marder SR and 2 others. J Clin Psychiatry, 1997. Cited by 683 papers, by iCite.
Cite this record
ConductScience Library. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Papers, record 9448657. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9448657
- Disease
- schizophrenia345 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Risperidone | Major topic |
| Schizophrenia | Major topic |
| Schizophrenic Psychology | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Basal Ganglia Diseases | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Factor Analysis, Statistical | |
| Female | |
| Haloperidol | |
| Humans | |
| Male | |
| Middle Aged | |
| Placebos | |
| Psychiatric Status Rating Scales | |
| Schizophrenia, Paranoid | |
| Severity of Illness Index | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00249132 | A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia | Results |
Source ClinicalTrials.gov
Cited by241
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 683 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42936181 | The Effects of Erratic Ratings on Placebo Response and Signal Detection in the Roche Bitopertin Phase 3 Negative Symptom Studies-A Post Hoc Analysis. | Schizophr Bull Open | 2020 | https://conductscience.org/library/papers/42936181 | PubMed |
| 42936133 | Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. | Schizophr Bull Open | 2020 | https://conductscience.org/library/papers/42936133 | PubMed |
| 42922680 | Longitudinal Brain Correlates of Cognitive Performance in Early Psychosis. | medRxiv | 2026 | https://conductscience.org/library/papers/42922680 | PubMed |
| 42761248 | Beyond single-person paradigms: N400 alterations in a social context in schizophrenia. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42761248 | PubMed |
| 42706283 | Revisiting symptom dimensions in schizophrenia with exploratory graph analysis. | Schizophrenia (Heidelb) | 2026 | https://conductscience.org/library/papers/42706283 | PubMed |
| 42621264 | The mechanism of action and clinical efficacy of xanomeline-trospium in schizophrenia: A comprehensive review. | Ther Adv Psychopharmacol | 2026 | https://conductscience.org/library/papers/42621264 | PubMed |
| 42401715 | Diagnostic and sex effects on frontostriatal brain wiring structural organization in early psychosis affective subjects compared to healthy controls. | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/42401715 | PubMed |
| 42356009 | Sharp-Wave EEG Activity and Cytomegalovirus Exposure in Schizophrenia Spectrum Disorders: A Neuroimmune Perspective. | J Clin Med | 2026 | https://conductscience.org/library/papers/42356009 | PubMed |
| 42123174 | Association of Depressive and Negative Symptoms with Quality of Life in Schizophrenia: A Cross-Sectional Inpatient Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42123174 | PubMed |
| 42111925 | Assessment of serum inflammatory cytokines in first-episode psychosis: Cross-sectional study. | S Afr J Psychiatr | 2026 | https://conductscience.org/library/papers/42111925 | PubMed |
| 42018313 | Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial. | JAMA Psychiatry | 2026 | https://conductscience.org/library/papers/42018313 | PubMed |
| 42011073 | Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). | Eur Psychiatry | 2026 | https://conductscience.org/library/papers/42011073 | PubMed |
| 41800547 | High-density EEG study in patients with schizophrenia treated with cariprazine. | Int J Neuropsychopharmacol | 2026 | https://conductscience.org/library/papers/41800547 | PubMed |
| 41597316 | Prevalence of Primary, Prominent, and Predominant Negative Symptoms of Schizophrenia in Routine Inpatient Psychiatric Care. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41597316 | PubMed |
| 41388146 | Rate and predictors of remission and recovery in first-episode psychosis: A 12-year follow-up of randomized-controlled trial on early intervention. | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/41388146 | PubMed |
| 41384453 | Confirmatory factor analysis of competing PANSS negative symptom models: data from OPTiMiSE first-episode schizophrenia study. | BJPsych Open | 2025 | https://conductscience.org/library/papers/41384453 | PubMed |
| 41369302 | The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study. | Int Clin Psychopharmacol | 2026 | https://conductscience.org/library/papers/41369302 | PubMed |
| 41321712 | Psychometric Properties and Factor Structure of the Arabic Translation of the Brief Negative Symptom Scale. | Complex Psychiatry | 2025 | https://conductscience.org/library/papers/41321712 | PubMed |
| 41311559 | Quantifying Exploratory Behavior In The Human Behavioral Pattern Monitor Using Automated Video Tracking. | Meth Psychol | 2025 | https://conductscience.org/library/papers/41311559 | PubMed |
| 41272239 | Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia. | CNS Drugs | 2026 | https://conductscience.org/library/papers/41272239 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| HALOPERIDOL | CHEMBL54 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL54 | ChEMBL |
| RISPERIDONE | CHEMBL85 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL85 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9448657
GET https://conductscience.org/api/papers/v1/9448657/cited_by?page=2